Recombinant Human Prourokinase Is Not a Superior Thrombolytic Agent for the Treatment of Stroke Compared to alteplase.

Published Date: 03 Aug 2023

In comparison to alteplase treatment, intravenous thrombolysis with recombinant human prourokinase resulted in a 16 point 4 percent lower risk of systemic bleeding, which was consistent with prior phase 2 data.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers find distinct cell receptors with the potential for new treatments.

2.

Breast cancer patients' arms swell less after an effective lymph node transfer.

3.

Telehealth in the pandemic era resulted in fewer therapy interruptions.

4.

Too Many Chest CTs for Incidental Lung Nodules?

5.

Global warming could be driving up women's cancer risk, find researchers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot